Lidia Anguiano
YOU?
Author Swipe
View article: Drug Testing for Residual Progression of Diabetic Kidney Disease in Mice Beyond Therapy with Metformin, Ramipril, and Empagliflozin
Drug Testing for Residual Progression of Diabetic Kidney Disease in Mice Beyond Therapy with Metformin, Ramipril, and Empagliflozin Open
Significance Statement Assessing a drug in a disease model more closely replicates the clinical situation if standard drugs are included in the study design. In a progressive-stage mouse model of obesity-related type 2 diabetes, bromoindir…
View article: P0967ENHANCING PODOCYTE REGENERATION WITH BROMOINDIRUBIN-3´-OXIME (BIO) AS A POTENTIAL TERAPEUTIC TARGET IN DIABETIC KIDNEY DISEASE
P0967ENHANCING PODOCYTE REGENERATION WITH BROMOINDIRUBIN-3´-OXIME (BIO) AS A POTENTIAL TERAPEUTIC TARGET IN DIABETIC KIDNEY DISEASE Open
Background and Aims Diabetic nephropathy (DN) is a leading cause of end-stage kidney disease. RAS and SGLT2 inhibitors are well established in reducing the progression of DN in early stages but true tissue regeneration is not achieved. BIO…
View article: The glomerular crescent
The glomerular crescent Open
Knowing the upstream mechanisms that triggered crescent formation provides a tool for the development of therapeutic interventions for CGN.
View article: The Long Pentraxin PTX3 Is an Endogenous Inhibitor of Hyperoxaluria-Related Nephrocalcinosis and Chronic Kidney Disease
The Long Pentraxin PTX3 Is an Endogenous Inhibitor of Hyperoxaluria-Related Nephrocalcinosis and Chronic Kidney Disease Open
The long pentraxin 3 (PTX3) exerts a variety of regulatory functions in acute and chronic tissue inflammation. In particular, PTX3 acts as an opsonin for a variety of pathogens and endogenous particles. We hypothesized that PTX3 would exhi…
View article: Sex dimorphism in ANGII-mediated crosstalk between ACE2 and ACE in diabetic nephropathy
Sex dimorphism in ANGII-mediated crosstalk between ACE2 and ACE in diabetic nephropathy Open
View article: SuO027ENDOGENOUS PENTRAXIN 3 INHIBITS NEPHROCALCINOSIS AND PROTECTS FROM HYPEROXALURIA-INDUCED CHRONIC KIDNEY DISEASE
SuO027ENDOGENOUS PENTRAXIN 3 INHIBITS NEPHROCALCINOSIS AND PROTECTS FROM HYPEROXALURIA-INDUCED CHRONIC KIDNEY DISEASE Open
View article: FP410AN OPTIMIZED ANIMAL MODEL OF PROGRESSIVE CKD IN TYPE 2 DIABETES TO IMPROVE PREDICTABILITY OF PRECLINICAL DRUG TESTING
FP410AN OPTIMIZED ANIMAL MODEL OF PROGRESSIVE CKD IN TYPE 2 DIABETES TO IMPROVE PREDICTABILITY OF PRECLINICAL DRUG TESTING Open
measurement of albuminuria.A combination of UD-014 and losartan showed synergistic effects in ZSF1 rats.In vitro cellular investigation revealed that SSAO induced oxidative stress in endothelial cells, leading to cellular dysfunction and i…
View article: SO024CIRCULATING ANGIOTENSIN CONVERTING ENZYME 2 ACTIVITY AS A BIOMARKER OF ATHEROSCLEROSIS PROGRESSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE
SO024CIRCULATING ANGIOTENSIN CONVERTING ENZYME 2 ACTIVITY AS A BIOMARKER OF ATHEROSCLEROSIS PROGRESSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE Open
View article: Endothelin Blockade in Diabetic Kidney Disease
Endothelin Blockade in Diabetic Kidney Disease Open
Diabetic kidney disease (DKD) remains the most common cause of chronic kidney disease and multiple therapeutic agents, primarily targeted at the renin-angiotensin system, have been assessed. Their only partial effectiveness in slowing down…
View article: Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease
Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease Open
Circulating ACE2 and ACE activities can be measured in human EDTA-plasma samples with zinc added to recover enzymatic activity. In a CKD population without previous history of CV disease, ACE2 activity from human EDTA-plasma samples direct…